Alessandro Rambaldi
#115,795
Most Influential Person Now
Researcher
Alessandro Rambaldi's AcademicInfluence.com Rankings
Alessandro Rambaldicomputer-science Degrees
Computer Science
#4510
World Rank
#4757
Historical Rank
Computational Linguistics
#448
World Rank
#455
Historical Rank
Machine Learning
#905
World Rank
#918
Historical Rank
Artificial Intelligence
#1120
World Rank
#1140
Historical Rank
Download Badge
Computer Science
Alessandro Rambaldi's Degrees
- PhD Computer Science University of Milan
- Masters Computer Engineering Polytechnic University of Milan
- Bachelors Computer Engineering Polytechnic University of Milan
Similar Degrees You Can Earn
Why Is Alessandro Rambaldi Influential?
(Suggest an Edit or Addition)Alessandro Rambaldi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease (1999) (1191)
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia (2017) (1188)
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013) (1143)
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. (2015) (951)
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. (2000) (661)
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) (586)
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (2014) (552)
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study (2013) (506)
- Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. (2007) (454)
- CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. (2001) (444)
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). (2012) (424)
- Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). (2009) (396)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (2019) (394)
- Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice (2008) (369)
- ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. (2011) (367)
- Recombinant human interleukin 5 is a selective eosinophil chemoattractant (1989) (337)
- Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden (2007) (328)
- Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. (2012) (328)
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 (2010) (322)
- Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. (2007) (306)
- Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. (2010) (301)
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. (2017) (292)
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. (2011) (290)
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. (2017) (287)
- Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. (1992) (281)
- High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. (2017) (281)
- Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. (2011) (278)
- PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (274)
- Rituximab in idiopathic membranous nephropathy. (2012) (268)
- Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. (2017) (265)
- Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. (1991) (260)
- JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. (2007) (250)
- Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia (1992) (246)
- Expression of the M-CSF (CSF-1) gene by human monocytes. (1987) (245)
- Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation (2006) (243)
- Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. (2008) (243)
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. (2015) (241)
- Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. (2010) (238)
- A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms (2010) (235)
- Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. (2011) (232)
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. (2008) (231)
- Induction of monocyte migration by recombinant macrophage colony-stimulating factor. (1988) (224)
- Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). (2003) (219)
- Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone (2001) (219)
- Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. (1988) (218)
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. (2013) (215)
- Thrombosis in primary myelofibrosis: incidence and risk factors. (2009) (213)
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group (2015) (211)
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. (2011) (208)
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. (2009) (207)
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis (2017) (205)
- Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias (1990) (205)
- Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. (1987) (202)
- WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). (2008) (196)
- Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation (2019) (194)
- Independent regulation of M-CSF and G-CSF gene expression in human monocytes. (1988) (193)
- Leukocytosis and risk stratification assessment in essential thrombocythemia. (2007) (192)
- Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. (1992) (191)
- Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. (2014) (190)
- Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. (2011) (186)
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab (2011) (186)
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus (2020) (185)
- Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. (2016) (183)
- AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. (2011) (178)
- Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. (2020) (177)
- Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. (2007) (173)
- Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. (2010) (173)
- Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. (2005) (171)
- Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. (2002) (167)
- Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. (1987) (165)
- Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia (2015) (165)
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea (2013) (164)
- Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. (2000) (164)
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 (2011) (162)
- Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts (2007) (159)
- Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. (2002) (156)
- Proposed definition of ‘poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo (2011) (156)
- Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation (2013) (154)
- Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? (2009) (150)
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. (2011) (148)
- Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. (2011) (148)
- Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis (2017) (146)
- Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. (2007) (145)
- Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study (2010) (145)
- Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome (2002) (143)
- Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. (1991) (143)
- Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. (2018) (141)
- Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. (2014) (141)
- Autologous hematopoietic stem cell transplantation in multiple sclerosis (2015) (140)
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria (2012) (139)
- Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome (2007) (139)
- Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. (2000) (137)
- Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support (2020) (134)
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy (2015) (134)
- Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. (1991) (133)
- Ruxolitinib‐associated infections: A systematic review and meta‐analysis (2018) (133)
- Interleukin-1β and tumor necrosis factor-α induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells (1991) (133)
- Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. (2015) (133)
- Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). (2014) (133)
- MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. (2014) (132)
- Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses (2011) (132)
- Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. (2007) (130)
- Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. (1989) (129)
- Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. (1988) (128)
- Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy (2015) (127)
- Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8 (1999) (124)
- Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. (2003) (123)
- Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect (2012) (122)
- Molecular histogenesis of posttransplantation lymphoproliferative disorders. (2003) (121)
- Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. (2017) (121)
- Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib (2013) (121)
- Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. (1997) (119)
- A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy (2013) (118)
- Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. (2008) (115)
- Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (2015) (115)
- Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab (2020) (112)
- Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. (2005) (111)
- RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. (1991) (110)
- miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. (2014) (110)
- Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. (2022) (109)
- Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN (2012) (109)
- The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells (2007) (108)
- Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation (2008) (108)
- Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. (2011) (105)
- Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. (1992) (105)
- In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. (2014) (103)
- Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy (2013) (101)
- Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases (2000) (101)
- High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. (2012) (100)
- Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. (2009) (100)
- T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells (1985) (99)
- Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea. (2019) (99)
- Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics (2013) (98)
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma (2010) (97)
- Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. (2004) (97)
- JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. (2009) (97)
- Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. (1993) (95)
- Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils. (1990) (95)
- Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts (2018) (92)
- Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation (2006) (91)
- Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. (2012) (91)
- Effect of alemtuzumab on neoplastic B cells. (2004) (90)
- FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab (2007) (89)
- Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. (2012) (89)
- Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey (2017) (87)
- The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F (2008) (87)
- Inflammation and myeloproliferative neoplasms. (2017) (86)
- Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT (2014) (85)
- Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry (2008) (83)
- Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. (1991) (79)
- Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy (2018) (79)
- Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (2018) (79)
- Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients (2012) (78)
- Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 (2020) (78)
- Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. (2014) (76)
- Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons Learned from First Clinical Trials (2013) (75)
- White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. (2015) (75)
- Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma (2014) (75)
- Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. (2003) (74)
- IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study (2020) (74)
- Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. (2014) (72)
- Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. (1994) (71)
- Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study (2012) (71)
- The Novel Synthetic Retinoid 6-(3-adamantyl-4-hydroxyphenyl)-2-naphthalene Carboxylic Acid (CD437) Causes Apoptosis in Acute Promyelocytic Leukemia Cells Through Rapid Activation of Caspases (1999) (71)
- A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2 (2012) (71)
- Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial (2018) (71)
- Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients (2014) (70)
- Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group (2009) (70)
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib (2021) (69)
- A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. (1990) (69)
- Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group (2016) (69)
- FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. (2007) (69)
- Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. (2016) (69)
- Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. (2008) (67)
- Autoimmunity and b‐cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells (1989) (67)
- Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes (2021) (66)
- Extracorporeal Photochemotherapy for the Treatment of Chronic Graft‐Versus‐Host Disease: Trend for a Possible Cell Dose‐Related Effect? (2007) (66)
- Molecular profile of Epstein–Barr virus infection in HHV-8-positive primary effusion lymphoma (2000) (66)
- Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (2012) (64)
- Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) (2010) (64)
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. (2019) (64)
- Masked polycythemia vera diagnosed according to WHO and BCSH classification (2014) (64)
- Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. (2013) (63)
- Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. (2010) (63)
- AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. (1996) (63)
- The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). (2008) (63)
- Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. (1989) (62)
- The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy (2013) (62)
- Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. (2020) (61)
- Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha. (2009) (61)
- Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. (2019) (61)
- Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. (2017) (61)
- Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project (2014) (61)
- Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring (2012) (60)
- Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia (2014) (60)
- Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). (2009) (60)
- T cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic large granular lymphocytes/natural killer cells. (1987) (60)
- A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. (2002) (59)
- The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT (2013) (59)
- Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. (1994) (59)
- Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches (2014) (58)
- Masked polycythemia Vera (mPV): Results of an international study (2013) (58)
- JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. (2011) (58)
- Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel (2020) (57)
- Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. (2011) (57)
- Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. (2005) (57)
- Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. (2016) (57)
- Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. (2015) (56)
- Masked polycythemia Vera (mPV): Results of an international study (2014) (56)
- Intraperitoneal administration of interferon β in ovarian cancer patients (1985) (55)
- Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma (2013) (55)
- Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha. (2001) (55)
- CEBPA–double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features (2016) (54)
- Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) (2010) (54)
- Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. (1995) (53)
- Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles (2015) (53)
- Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia (2008) (53)
- Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). (2014) (52)
- Expression of c-jun protooncogene in human myelomonocytic cells. (1989) (52)
- Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome (2013) (51)
- A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. (2009) (51)
- HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry (2009) (51)
- Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. (2016) (51)
- Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. (2010) (51)
- Phospholipid‐dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia (2014) (51)
- Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphoma (2010) (50)
- Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis (2013) (50)
- Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. (2015) (49)
- Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients (2015) (49)
- Interferon‐γ induces expression of the interleukin 2 receptor gene in human monocytes (1987) (49)
- Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou (2006) (48)
- Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia (2010) (48)
- Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. (2017) (48)
- Expression of leukocyte alkaline phosphatase gene in normal and leukemic cells: regulation of the transcript by granulocyte colony-stimulating factor. (1990) (47)
- Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. (2001) (46)
- Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study (2021) (46)
- A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera (2014) (46)
- Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies (2016) (45)
- Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia (2019) (45)
- High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program (2013) (45)
- Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. (2005) (45)
- Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo (2005) (45)
- Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (2018) (44)
- The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera (2017) (44)
- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs. (2020) (44)
- Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma (2002) (43)
- Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia (2019) (43)
- Characterization of the human myeloid leukemia‐derived cell line GF‐D8 by multiplex fluorescence in situ hybridization, subtelomeric probes, and comparative genomic hybridization (1999) (43)
- Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. (1998) (43)
- Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group (2016) (43)
- Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement (2015) (43)
- Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. (1996) (43)
- All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. (1995) (43)
- Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. (2017) (42)
- Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) (2018) (41)
- Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study (2017) (41)
- Phosphodiesterase IV Inhibition by Piclamilast Potentiates the Cytodifferentiating Action of Retinoids in Myeloid Leukemia Cells (2004) (40)
- The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. (2012) (40)
- Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. (2000) (40)
- High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation (2017) (40)
- Differences in the expression of alkaline phosphatase mRNA in chronic myelogenous leukemia and paroxysmal nocturnal hemoglobinuria polymorphonuclear leukocytes. (1989) (40)
- Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms (2017) (40)
- Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. (2014) (39)
- Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). (1997) (39)
- COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study (2021) (39)
- Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial (2019) (39)
- Cerebral vein thrombosis in patients with Philadelphia‐negative myeloproliferative neoplasms An European Leukemia Net study (2014) (38)
- Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies (2021) (38)
- Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia (2016) (38)
- Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. (2006) (38)
- Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial (2019) (38)
- Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease (2016) (38)
- Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. (2021) (38)
- Intensification of salvage treatment with high‐dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non‐Hodgkin's lymphoma (2001) (37)
- Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine (2018) (37)
- ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. (2013) (37)
- Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera (2017) (37)
- Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients (2017) (36)
- Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b (2010) (36)
- Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (2017) (36)
- Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. (2019) (36)
- Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) (2014) (35)
- Identification of DNA rearrangements at the retinoic acid receptor-alpha (RAR-alpha) locus in all patients with acute promyelocytic leukemia (APL) and mapping of APL breakpoints within the RAR-alpha second intron. Italian Cooperative Study Group "GIMEMA". (1992) (35)
- Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. (2001) (35)
- The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (2013) (35)
- SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. (2020) (35)
- Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (2021) (35)
- Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia (2014) (34)
- Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias (1996) (34)
- PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA (2013) (34)
- Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors (2012) (34)
- ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG (2012) (34)
- Induction of monocyte-macrophage procoagulant activity by transformed cell lines. (1986) (33)
- Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups (2008) (33)
- Aberrant somatic hypermutation in post‐transplant lymphoproliferative disorders (2004) (33)
- The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. (1999) (32)
- Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma (2011) (32)
- Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. (1995) (32)
- Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial (2012) (32)
- Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study (2015) (32)
- SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma (2013) (32)
- Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. (2013) (32)
- Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features (1992) (32)
- A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2 V617F Positive Chronic Myeloproliferative Neoplasms (2008) (32)
- Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? (2013) (32)
- Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation (2012) (31)
- Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). (2015) (31)
- A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). (2011) (31)
- Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells (1998) (31)
- Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 (2020) (30)
- Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. (1997) (30)
- Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy (1992) (30)
- Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. (1983) (30)
- Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia. (1996) (30)
- Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. (2013) (30)
- Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid. (1984) (30)
- Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study (2020) (30)
- Endothelial cells express the interleukin-1 receptor type I (1991) (30)
- Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols (2014) (29)
- Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives (2009) (29)
- interim Pet-adapted Chemotherapy In Advanced Hodgkin Lymphoma (hl). Results Of The Second Interim Analysis Of The Italian Gitil/fil Dh0607 Trial : 118 (2015) (29)
- Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. (2004) (29)
- Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. (2009) (29)
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 (2021) (29)
- Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. (1994) (28)
- Effects of dexamethasone on pro-inflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells. (1995) (28)
- Analysis of immunoglobulin heavy and light chain variable genes in post‐transplant lymphoproliferative disorders (2006) (28)
- Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions (2001) (28)
- Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. (2008) (28)
- Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence (2013) (28)
- The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. (2009) (27)
- Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. (2021) (27)
- Experts’ considerations on HLA‐haploidentical stem cell transplantation (2014) (27)
- Effect of all trans‐retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells (1997) (27)
- CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) (2011) (27)
- At the peak of Covid-19 age and disease severity but not comorbidities are predictors of mortality. Covid-19 burden in Bergamo, Italy. (2020) (27)
- Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. (2014) (27)
- CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis (2014) (27)
- Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response (2014) (27)
- The use of anthracyclines in adult acute lymphoblastic leukemia. (1995) (27)
- Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. (2014) (26)
- Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. (2016) (26)
- The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application. (1997) (26)
- High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen (2009) (26)
- High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study (2011) (25)
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (25)
- Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. (2020) (25)
- Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project (2018) (25)
- The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia (2013) (25)
- BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front‐line therapy for high‐risk patients with diffuse large cell lymphoma (1997) (25)
- Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. (2002) (25)
- Validation of the acute leukemia‐EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi‐center GITMO cohort (2017) (25)
- HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. (2019) (24)
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo). (2019) (24)
- Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation. (2013) (24)
- Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia (2004) (24)
- Establishment and characterization of a new granulocyte-macrophage colony-stimulating factor-dependent and interleukin-3-dependent human acute myeloid leukemia cell line (GF-D8). (1993) (24)
- Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival (2014) (24)
- Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia (2012) (24)
- Second cancers in MPN: Survival analysis from an international study (2019) (23)
- A Phase II Multiple Dose Clinical Trial of Histone Deacetylase Inhibitor ITF2357 in Patients with Relapsed or Progressive Multiple Myeloma: Preliminary Results. (2007) (23)
- A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms (2012) (23)
- Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival (2016) (23)
- Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07 (2020) (23)
- The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. (2006) (23)
- Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1) (2018) (23)
- ASXL1 mutations in primary and secondary myelofibrosis (2012) (23)
- Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL) (2016) (23)
- Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia (2015) (22)
- CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease (2012) (22)
- Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms (2017) (22)
- p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells (2012) (22)
- Second allogeneic stem cell transplant for aplastic anaemia: a retrospective study by the severe aplastic anaemia working party of the European society for blood and marrow transplantation (2015) (22)
- T cell receptor delta gene organization and expression in normal and leukemic natural killer cells. (1989) (22)
- Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation. (2000) (22)
- A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia (2022) (21)
- A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients (2015) (21)
- Interferons induce normal and aberrant retinoic‐acid receptors type α in acute promyelocytic leukemia cells: Potentiation of the induction of retinoid‐dependent differentiation markers (1996) (21)
- Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. (1993) (21)
- Stage I/II follicular lymphoma: spread of bcl‐2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy (2007) (21)
- Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. (1996) (21)
- Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high‐risk patients (2008) (21)
- Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase. (1995) (21)
- Molecular diagnosis and monitoring of acute myeloid leukemia. (1996) (21)
- Redundant functions of B-Myb and c-Myb in differentiating myeloid cells. (1997) (21)
- Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. (2013) (21)
- Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). (1999) (21)
- A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy (2014) (21)
- Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy (1988) (21)
- Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. (2022) (21)
- Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) (2017) (20)
- Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. (2019) (20)
- Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. (1993) (20)
- Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia (2019) (20)
- Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: Results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial (2007) (20)
- Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. (2013) (20)
- Induction‐consolidation with an idarubicin‐containing regimen, unpurged marrow autograft, and post‐graft chemotherapy in adult acute lymphoblastic leukaemia (1999) (20)
- Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study (2021) (19)
- Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency‐related non‐Hodgkin lymphomas (2011) (19)
- Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia (2019) (19)
- A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results (2010) (19)
- Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera (2012) (19)
- Determination of orally administered all-trans-retinoic acid in human plasma by high-performance liquid chromatography. (1994) (19)
- Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials (2020) (19)
- Effects of 1,25-dihydroxy vitamin D3 on all-trans retinoic acid sensitive and resistant acute promyelocytic leukemia cells. (1996) (19)
- No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials (2017) (19)
- Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis (2015) (18)
- RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF). (2009) (18)
- Long-term Results From a Phase II Open-label Study of Ruxolitinib in Patients With Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea (2014) (18)
- Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients (2017) (18)
- Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. (2005) (18)
- Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission (2017) (18)
- Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) (2008) (18)
- A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. (1997) (18)
- Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. (2017) (18)
- Endothelial cells express the interleukin-1 receptor type I. (1991) (18)
- Unexpected remission of acute myeloid leukaemia after GM‐CSF (1994) (17)
- G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. (1996) (17)
- Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia. (2018) (17)
- Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study (2011) (17)
- Interleukin‐1 and interleukin‐2 control granulocyte‐ and granulocyte‐macrophage colony‐stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia (1990) (17)
- Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. (2019) (17)
- Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. (2000) (17)
- Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study (2011) (17)
- Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab (2020) (17)
- Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia. (2018) (17)
- Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. (2019) (17)
- c-sis but not c-fos gene expression is lineage specific in human myeloid cells. (1988) (17)
- Transcriptional and post‐transcriptional regulation of IL‐1β, IL‐6 and TNF‐α genes in chronic lymphocytic leukaemia (1993) (17)
- Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia (2018) (17)
- Association of NK-cell lymphoproliferative disease and nephrotic syndrome. (1990) (16)
- Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. (1996) (16)
- From palliation to epigenetic therapy in myelofibrosis. (2008) (16)
- Expression of GATA-1 mRNA in human myeloid leukemic cells. (1994) (16)
- A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis (2019) (16)
- The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation. (2007) (16)
- Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis (2021) (16)
- Tyrosine kinases but not cAMP-dependent protein kinase mediate the induction of leukocyte alkaline phosphatase by granulocyte-colony-stimulating factor and retinoic acid in acute promyelocytic leukemia cells. (1995) (16)
- The role of anthracyclines in adult acute lymphoblastic leukaemia. (1996) (16)
- Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy (2016) (16)
- Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial (2016) (16)
- Large granular lymphocyte/natural killer cell proliferative disease: clinical and laboratory heterogeneity. (2009) (16)
- Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML (2021) (16)
- Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study (2015) (16)
- Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist. (1993) (15)
- Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology (2014) (15)
- Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. (2018) (15)
- Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients (2012) (15)
- Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. (2019) (15)
- Leucocyte alkaline phosphatase identifies terminally differentiated normal neutrophils and its lack in chronic myelogenous leukaemia is not dependent on p210 tyrosine kinase activity (1999) (15)
- Molecular characterization of a new recombination of the SIL/TAL‐1 locus in a child with T‐cell acute lymphoblastic leukaemia (2002) (15)
- Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy (2013) (15)
- Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. (1995) (14)
- Establishment of human acute myelogenous leukemia lines secreting interleukin‐1β in SCID mice (1995) (14)
- Consensus recommendations for improvement of unmet clinical needs--the example of chronic graft-versus-host disease: a systematic review and meta-analysis. (2015) (14)
- Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study. (2019) (14)
- Stat 1 Is Induced and Activated by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia Cells (1997) (14)
- Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. (2017) (14)
- Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia (1994) (14)
- Intraperitoneal administration of interferon beta in ovarian cancer patients. (1985) (14)
- Integrated use of morphology, cytochemistry, and immune marker analysis to identify acute leukaemia subtypes. (1989) (14)
- Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. (2006) (14)
- Flow cytometry of leucocyte alkaline phosphatase in normal and pathologic leucocytes (1997) (14)
- BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL) (2017) (13)
- THERAPY WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (1992) (13)
- Induction of cytotoxicity by interleukin‐2 in tγ‐lymphoproliferative disorders (1986) (13)
- Innovative cell-based therapies in onco-hematology: what are the clinical facts ? (2004) (13)
- IDH1-R132 changes vary according to NPM1 and other mutations status in AML (2019) (13)
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (13)
- CD123 Is Consistently Expressed on NPM1-Mutated AML Cells (2021) (13)
- Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response (2013) (13)
- Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia (2003) (13)
- Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. (2018) (13)
- Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. (2002) (13)
- Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: Improved results and revised prognostic criteria (1993) (13)
- A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. (1998) (13)
- Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT (2017) (13)
- Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Mesenchymal Stromal Cells: A Prospective, Multicentric, Phase 1 Study (2013) (13)
- Lymphokine Production in Ty Lymphoproliferative Disorders (1986) (13)
- Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial (2022) (13)
- Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy (2022) (13)
- Therapy of myelofibrosis (excluding JAK2 inhibitors) (2010) (13)
- The EBMT–ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis (2017) (13)
- A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy (2011) (13)
- Molecular genetics of the t(15;17) of acute promyelocytic leukemia (APPL). (1992) (13)
- Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients (2019) (13)
- Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis (2011) (12)
- Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program (2021) (12)
- Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. (2018) (12)
- Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. (2010) (12)
- A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis (2020) (12)
- Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies (2021) (12)
- Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1. (1992) (11)
- Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy (2021) (11)
- Constitutive expression of IL‐1β, M‐CSF and c‐fms during the myeloid blastic phase of chronic myelogenous leukaemia (1992) (11)
- Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children (2016) (11)
- Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation? (2017) (11)
- Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission (2018) (11)
- Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. (2019) (11)
- Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. (1997) (11)
- Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial (2014) (11)
- Bergamo and Covid-19: How the Dark Can Turn to Light (2020) (11)
- PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias (2017) (11)
- Monoclonal lymphocytosis with villous lymphocytes: a chronic lymphoproliferative disease of CD11c+ B-cells. (1991) (11)
- Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. (2021) (10)
- A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. (2014) (10)
- Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas (2015) (10)
- A short low‐dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes (2009) (10)
- Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. (2019) (10)
- Long-term follow-up of recovered MPN patients with COVID-19 (2021) (10)
- Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status (2016) (10)
- Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. (2002) (10)
- Long‐term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non‐Hodgkin's lymphoma (1997) (10)
- Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era? (2016) (10)
- Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. (2001) (10)
- Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study (2020) (10)
- Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT). (2005) (10)
- Quality of harvest and role of cell dose in unrelated bone marrow transplantation: An Italian Bone Marrow Donor Registry–Gruppo Italiano Trapianto di Midollo Osseo Study (2014) (10)
- Impact of detectable measurable residual disease on umbilical cord blood transplantation (2020) (10)
- High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults (2015) (9)
- Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue (2013) (9)
- RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells (2016) (9)
- Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients (2020) (9)
- Acute Myeloid Leukemia Relapses after Allogenenic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation (2014) (9)
- Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06 (2020) (9)
- Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. (2020) (9)
- PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). (2016) (8)
- Distinct Hemostatic Profile of Leukocytes in Essential Thrombocythemia (ET) Carrying the JAK2 V617F Mutation. (2005) (8)
- Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. (2017) (8)
- Investigation of chronic lymphocytosis in adults. (1988) (8)
- The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs), (2011) (8)
- Activated FVII-Antithrombin Complex and Tissue Factor mRNA As Potential Markers of Severe Thrombo-Hemorrhagic Syndrome in APL Patients (2011) (8)
- Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma (2020) (8)
- Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial (2019) (8)
- Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Pha (2017) (8)
- The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells (2018) (8)
- Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. (2017) (8)
- Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (8)
- Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia. (2020) (8)
- Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma (2007) (7)
- Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease. (2004) (7)
- The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. (2013) (7)
- Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient (2014) (7)
- Incidence of novel N‐glycosylation sites in the B‐cell receptor of lymphomas associated with immunodeficiency (2004) (7)
- Early serum TARC reduction predicts prognosis in advanced‐stage Hodgkin lymphoma patients treated with a PET‐adapted strategy (2020) (7)
- Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes (2020) (7)
- Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes (2018) (7)
- TP53 in adult acute lymphoblastic leukemia (2018) (7)
- P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL (2022) (7)
- Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party (2017) (7)
- Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis (2021) (7)
- Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL) (2012) (7)
- Concurrent Diagnosis of Acute Myeloid Leukemia and Symptomatic COVID-19 Infection: a Case Report Successfully Treated with Azacitidine-Venetoclax Combination (2021) (7)
- Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis (2021) (7)
- Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS (2012) (7)
- A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results (2016) (7)
- Treatment with Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation (2015) (7)
- Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 (2020) (7)
- Role of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia (2014) (7)
- S1617 A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY (2019) (7)
- The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET‐2‐adapted HD0607 trial (2020) (7)
- Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia (2014) (7)
- Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. (2021) (7)
- Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
- Second versus first wave of COVID-19 in patients with MPN (2022) (6)
- Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD (2010) (6)
- Transcriptional and post-transcriptional regulation of IL-1 beta, IL-6 and TNF-alpha genes in chronic lymphocytic leukaemia. (1993) (6)
- A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1) (2021) (6)
- Low levels of ADAMTS‐13 with high anti‐ADAMTS‐13 antibodies during remission of immune‐mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi‐institutional study (2020) (6)
- Involvement of MAF / SPP 1 axis in the development of bone marrow fi brosis in PMF patients (2017) (6)
- Next‐generation sequencing for BCR‐ABL1 kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper (2020) (6)
- Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (6)
- Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic scoring System (IPSS-R) (2014) (6)
- Intensive retreatment of adults and children with acute lymphoblastic leukemia (1992) (6)
- Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome. (1993) (6)
- Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation. (2006) (6)
- Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: A remission induction therapy for aggressive pediatric post‐transplant lymphoproliferative disease (PTLD) (2011) (6)
- The chronic proliferative disease of large granular lymphocytes. (1989) (6)
- Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy (2018) (6)
- Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group (2019) (6)
- Expansion of B cell precursors after unrelated cord blood transplantation for an adult patient (2007) (6)
- Interleukin-1 and glomerular mesangial cells. (1993) (6)
- Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT (2020) (6)
- Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) (2014) (6)
- Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin’s lymphoma (1996) (6)
- Clinical Significance of JAK2 V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients. (2006) (6)
- Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) (2019) (6)
- Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. (2018) (6)
- The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients (2012) (6)
- Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. (1993) (6)
- Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization. (1996) (6)
- Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) (2018) (6)
- Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients (2012) (5)
- Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia (2020) (5)
- Selective Targeting of the JAK2V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor. (2007) (5)
- Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation (2016) (5)
- Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group (2016) (5)
- A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients (2013) (5)
- Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis (2015) (5)
- Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study (2018) (5)
- Suicide gene therapy and the control of graft-vs-host disease. (2004) (5)
- A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results (2011) (5)
- Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (2022) (5)
- Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. (1996) (5)
- Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. (2014) (5)
- Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis. (2005) (5)
- Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins. (2009) (5)
- A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma (2020) (5)
- Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia (2022) (5)
- Characteristics of graft‐versus‐host disease occurring after alemtuzumab‐containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival (2019) (5)
- A PHASE 1/2 Clinical Trial of Brentuximab-Vedotin and Bendamustin in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (HALO STUDY. NCT identifier : 02467946): Preliminary Report (2016) (5)
- Worldwide Examination of Patients with CLL Hospitalized for COVID-19 (2020) (5)
- Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
- Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study (2018) (4)
- Narsoplimab (OMS721), a Masp-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA) (2021) (4)
- Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy (2020) (4)
- miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis (2014) (4)
- Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia. (1999) (4)
- TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY (2017) (4)
- Acute Lymphoblastic Leukaemia Cells Carrying the t(12;21) Translocation Are Highly Sensitive to Alemtuzumab Mediated Cell Lysis. (2005) (4)
- High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG) (2020) (4)
- Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients. (2006) (4)
- Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (2020) (4)
- Mobilization of peripheral blood hematopoietic stem cells by granulocyte-colony stimulating factor and plerixafor in patients with cardiac AL amyloidosis (2015) (4)
- Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT (2021) (4)
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients (2010) (4)
- Evaluation and Counseling of Candidates (2018) (4)
- Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up (2014) (4)
- A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results (2017) (4)
- Identification of DNA Rearrangements at the Retinoic Acid Receptor-a ( RARa ) Locus in All Patients With Acute Promyelocytic Leukemia ( APL ) and Mapping of APL Breakpoints Within the RARa Second Intron (2003) (4)
- WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo. (2007) (4)
- Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2019) (4)
- Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS. (2006) (4)
- Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm (2015) (4)
- Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study (2022) (4)
- Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients. (2011) (4)
- Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings (2019) (4)
- Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study (2019) (4)
- Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin (2019) (4)
- Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01 (2022) (4)
- A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results (2013) (3)
- Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use : a Retrospective Evaluation of 1334 Patients (2014) (3)
- Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL). (2006) (3)
- OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa (2021) (3)
- New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? (2017) (3)
- Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study (2015) (3)
- Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL). (2005) (3)
- The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab (2012) (3)
- MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL (2021) (3)
- Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission (2019) (3)
- Improved Clinical Outcome of Adult Patients with Ph+ ALL After a Combined Imatinib-Chemotherapy Induction/Consolidation Program Followed by Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Prospective Study of the Northern Italy Leukemia Group (2010) (3)
- MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis (2017) (3)
- Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population (2016) (3)
- One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity (2022) (3)
- Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. (1987) (3)
- The Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with Recurring Hodgkin’s Lymphoma: An EBMT Study on 151 Patients. (2007) (3)
- Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial (2022) (3)
- Myeloid Malignancies (2022) (3)
- A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease (2015) (3)
- Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial. (2005) (3)
- Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study) (2014) (3)
- Bone Marrow BCL2/IgH+ Cells at Diagnosis and Not FCGRIIIA Polymorphism Predict Response in Follicular Non-Hodgkin’s Lymphoma Patients Treated with Sequential CHOP and Rituximab. (2005) (3)
- Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients (2015) (3)
- No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials (2017) (3)
- Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study (2019) (3)
- The natural history of monoclonal villous lymphocytosis: a chronic lymphoproliferative disorder of CD11c+ B cells. (1996) (3)
- Production of Interleukin 1 but not of Procoagulant Activity by Large Granular Lymphocytes (1985) (3)
- Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study (2022) (3)
- Targeting CDK 6 and BCL 2 Exploits the " MYB Addiction " of Ph + Acute Lymphoblastic Leukemia (2018) (3)
- Short-course imatinib (IM) added to chemotherapy improves early but not long-term outcome in adult Ph/BCR-ABL+ acute lymphoblastic leukemia (ALL) : 5-year follow-up results of study NILG-09 (2008) (3)
- A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML (2019) (3)
- CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL (2019) (3)
- The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS (2010) (3)
- Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study (2020) (3)
- Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms (2013) (3)
- A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL (2007) (3)
- Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients. (2008) (3)
- Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis (2007) (3)
- Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for > 55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT (2014) (3)
- Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis. (2004) (3)
- Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) Among Adults with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) Achieving Remission with Blinatumomab (2016) (3)
- Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG) (2014) (3)
- Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome (2007) (3)
- IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. (2021) (2)
- Reply to H.J.A. Adams et al and C. Mesguich et al. (2018) (2)
- Role of anthracycline dose intensity in adult Philadelphia chromosome/BCR-ABL positive and negative B-lineage acute lymphoblastic leukemia (1999) (2)
- A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis. (2007) (2)
- Second Versus First Wave of COVID-19 in Patients with MPN (2021) (2)
- Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT. (1995) (2)
- Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse (2020) (2)
- Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial (2020) (2)
- Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R) (2014) (2)
- Determinants of thrombin generation in gynaecological malignancies (2016) (2)
- Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RAR a and PML-RAR a (2001) (2)
- Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. (2022) (2)
- A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study (2022) (2)
- Platelet Adhesion Under Flow Condition in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV): Analysis According to the Mutational Status (2015) (2)
- Nodal aggressive non-Hodgkin’s lymphoma in the adult: a review article (2005) (2)
- PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) (2015) (2)
- Splenectomy before allogeneic hematopoietic stem‐cell transplantation for myelofibrosis: Tumor burden matters! (2020) (2)
- Monoclonal antibody therapy of adult acute lymphoblastic leukemia: progress and challenge for new clinical trials (2013) (2)
- Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07 (2010) (2)
- Chemoimmunotherapy With R-chop Or High Dose Sequential Therapy (r-hds) With Autologous Stem Cell Transplantation (asct) For High Risk Dlbcl Patients: Preliminary Results Of The Randomized Rhds0305 Trial By Gruppo Italiano Terapie Innovative Nei Linfomi (gitil): 120 (2013) (2)
- PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2019) (2)
- An agenda for future research projects in polycythemia vera and essential thrombocythemia (2020) (2)
- Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy (2013) (2)
- Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting (2013) (2)
- FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients (2022) (2)
- BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FIL HD0607 TRIAL (2021) (2)
- Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial (2012) (2)
- IMMUNOBIOLOGY Glycoengineered CD 20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD 16 B more ef fi ciently than rituximab (2013) (2)
- Preliminary Results of a Risk-Oriented Program for B-Lineage Adult Acute Lymphoblastic Leukemia (ALL): The Collaborative Italian Study 08/96 (2001) (2)
- Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term (2021) (2)
- Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO) (2014) (2)
- In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome (2012) (2)
- BEACOPP Chemotherapy Is Able to Induce Durable Complete Remission in Poor-Prognosis Hodgkin’s Lymphoma Patients with a Positive Interim PET after 2 ABVD Cycles (2008) (2)
- Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs) (2015) (2)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL): An analysis based on EBMT registry. (2007) (2)
- Associations between gender , disease features and symptom burden in the MPN population : An analysis by the MPN QOL International Working Group (2016) (2)
- A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group (2014) (2)
- Comparison of RIC-alloHCT and autoHCT for > 55 years old patients with acute lymphoblastic leukemia: an analysis from Acute Leukemia Working Party of the EBMT (2015) (2)
- Targeting Mutant BRAF with Vemurafenib in Relapsed or Refractory Hairy Cell Leukemia (2016) (2)
- Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts (2017) (2)
- Overlapping features of therapy-related and de novoNPM1-mutated AML. (2022) (2)
- Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study (2015) (2)
- Brief report Characteristics and clinical correlates of MPL 515WL/K mutation in essential thrombocythemia (2016) (2)
- High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect (2013) (2)
- Immunological and genotypic analysis of human Tγ-lymphoproliferative disorders (1986) (2)
- Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (2017) (2)
- Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey. (2009) (2)
- NK leukemia: a rare case of oral manifestations representing the initial sign. (2013) (2)
- Increased Platelet Thrombus Formation Under Flow Condition In Myeloproliferative Neoplasms (MPN) (2013) (2)
- Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment. (2007) (2)
- Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (2019) (2)
- Constitutive Expression of GATA-1 , EPOR , &-Globin , and y-Globin Genes in Myeloid Clonogenic Cells From Juvenile Chronic Myelocytic Leukemia (2)
- Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS) (2011) (2)
- Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis (2018) (2)
- Enhanced killing of human B lymphoma targets by combined use of cytokine induced killer ( CIK ) cultures and anti-CD 20 antibodies (2010) (2)
- Establishment and characterization of a new granulocyte-macrophage colony-stimulating factor-dependent and interleukin-3-dependent human acute myeloid leukemia cell line (GF-D8) (1993) (2)
- Modern therapy of young and adult Ph-ALL. (2012) (2)
- Pegylated interferon alpha-2a in patients with myeloproliferative neoplasms (MPN): international experience in 115 cases (2012) (1)
- Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients (2013) (1)
- The course of monoclonal ‘villous’ lymphocytosis over 15 years of follow-up: progression to SLVL or spontaneous clinical but not molecular remission (2003) (1)
- Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis (2014) (1)
- Risk-Adapted Therapy of Adult Acute Myeloid Leukemia (AML): Safety and Efficacy of Repetitive HD-ARA-C Courses with Low-Dose Autologous Blood Stem Cell Support. (2005) (1)
- Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study (2023) (1)
- Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML (2014) (1)
- Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia (2013) (1)
- Predominant Complement Mediated Lysis of B-CLL Cells by Therapeutic MAbs Rituximab and Campath-1H in Whole Blood Assays. (2009) (1)
- Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry (2011) (1)
- A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) (2011) (1)
- High inter‐follicular spatial co‐localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma (2022) (1)
- Outpatient Stem Cell Mobilization with Low and Intermediate Dose Cyclophosphamide Is a Safe and Effective Procedure in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation (2017) (1)
- Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study (2017) (1)
- Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2015) (1)
- Title: Achieving a Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long Term Outcome (2016) (1)
- Treosulfan - Fludarabine as Ablative Conditioning Regimen for Patients with High Risk Hematologic Malignancies. (2006) (1)
- Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT (2019) (1)
- Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients. (2009) (1)
- Organ-specific growth of a murine lymphoma of spontaneous origin in nude mice (1991) (1)
- Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity (2020) (1)
- Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT (2014) (1)
- Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia (2018) (1)
- Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06 (2019) (1)
- One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806. (2010) (1)
- The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study (2020) (1)
- Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases. (2007) (1)
- Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL). (2005) (1)
- New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVII-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA (2012) (1)
- A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. (2007) (1)
- Shc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8 (1998) (1)
- P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients (2007) (1)
- Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs (2015) (1)
- Limited Success with a Postremission Strategy Comprising Conventional Consolidation and High-Dose Treatment (HDT) with Autologous Peripheral Progenitor Cell (PBPC) Support for Adult Acute Lymphoblastic Leukaemia (ALL) (2003) (1)
- The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hogkin’s Lymphoma. (2005) (1)
- Migratory capacity of large granular lymphocytes from T-gamma-lymphoproliferative disorders. (1986) (1)
- Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial (2022) (1)
- Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL (2022) (1)
- Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT (2022) (1)
- Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease (2008) (1)
- Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group (2016) (1)
- Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT (2016) (1)
- Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLO-SCT). (2004) (1)
- S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS. (2022) (1)
- Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplant with in Vivo T-Cell Depletion By Alemtuzumab: Incidence, Outcome and Pattern of Organ Involvement (2014) (1)
- Lymphokine production in T gamma lymphoproliferative disorders. (1986) (1)
- PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. (2016) (1)
- Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations (2020) (1)
- Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse (2014) (1)
- Unrelated Hematopoietic Stem Cell Transplantation with Reduced Intensity Regimens in High Risk Patients for Age or Disease: Results from Two Independent Prospective GITMO Studies. (2005) (1)
- The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party (2011) (1)
- Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06 (2018) (1)
- Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (1)
- In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients. (2012) (1)
- Characterization of Cytokine Release Syndrome (CRS) in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma (RRMM) (2021) (1)
- Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT (2015) (1)
- Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL). (2012) (1)
- Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial (2021) (1)
- Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). (2006) (1)
- Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls (2019) (1)
- Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas (2015) (1)
- IN ADULT ACUTE MYELOID LEUKAEMIA (AML) ALL RISK SUBSETS BENEFIT FROM A SEQUENTIAL HIGH-DOSE PROGRAMME AS EARLY RESCUE OF FIRST INDUCTION FAILURE: A REPORT FROM NORTHERN ITALY LEUKAEMIA GROUP (NILG) (2010) (1)
- Inhibition of the lectin pathway of complement ameliorates hypocomplementemia and restores serum bactericidal activity in patients with severe COVID‐19 (2022) (1)
- Comorbidity Index: a prospective, multicenter GITMO study Validation of the Hematopoietic Cell Transplantation-Specific (2012) (1)
- Tandem transplant with autografting followed by non-myeloablative allografting for treatment of multiple myeloma: an Italian multi center trial (2003) (1)
- Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up. (2009) (1)
- Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience. (2006) (1)
- Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia : Results From The Prospective Long-Term Observational Exels Study (2016) (1)
- Immunomonitoring of Transplanted Patients Infused With Mesenchymal Stromal Cells (MSC) for Treating Steroid-Refractory GVHD (2011) (1)
- Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial (2022) (1)
- Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. (2008) (1)
- Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study (2014) (1)
- Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (2021) (1)
- Pleiotropic anti-myeloma activity of ITF 2357 : inhibition of IL-6 receptor signalling and repression of miR-19 a and miR-19 b by (2009) (1)
- T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial. (2021) (1)
- The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23). (2005) (1)
- Carboplatin-Based High-Dose Therapy for Refractory Acute Myeloid Leukaemia (1998) (1)
- Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies (2021) (1)
- Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19 (2022) (1)
- Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome (2016) (1)
- DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA (2021) (1)
- A Novel, Highly Sensitive, Rapid, Non-PCR Based Method for the Detection of the JAK2 V617F Mutation in Chronic Myeloproliferative Neoplasms. (2009) (1)
- Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL) (2013) (1)
- Real-world data: how they can help to improve quality of care (2021) (1)
- ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients (2010) (1)
- Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy (2016) (1)
- Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry (2012) (1)
- Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL (2022) (1)
- Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia (2010) (1)
- Procoagulant Cell Activities in Acute Leukemia (1992) (1)
- Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. (2019) (1)
- Rabbit anti-thymocyte globulin to prevent GVHD. (2016) (1)
- Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group (2016) (1)
- MULTI‐OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) ‐ INTERIM ANALYSIS OF IELSG46 STUDY (2019) (1)
- Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT (2011) (1)
- Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients (2014) (1)
- High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program (2012) (1)
- 16: Long-Term Results of a Gitmo Retrospective Study on Hematopoietic Stem Cell Transplantation (HSCT) for Paroxysmal Nocturnal Hemoglobinuria (PNH) (2008) (1)
- ENHANCED ALLOREACTIVITY TO BI-DIRECTIONAL NON-PERMISSIVE HLA-DPB1 MISMATCHES SUPPORTS NON-HIERARCHICAL T-CELL EPITOPE GROUP DIVERSITY AS UNDERLYING BIOLOGICAL MECHANISM (2013) (1)
- First report of the minimal residual disease-oriented GIMEMA LAL 1913 (2021) (1)
- PF510 A 14-GENE SIGNATURE ASSOCIATED TO CHOLESTEROL METABOLISM IDENTIFIES M1-LIKE TUMOR-INFILTRATING MACROPHAGES AND PREDICTS PATIENT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA (2019) (1)
- New drugs and allogeneic hematopoietic cell transplantation for hematological malignancies: potential roles as bridge to transplant, as consolidation or as part of the conditioning (2017) (1)
- AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST‐LINE THERAPY IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY (2019) (1)
- Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea (2010) (1)
- Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study (2022) (1)
- Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study. (2012) (1)
- Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients (2015) (1)
- Abstract CT057: Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (2017) (1)
- A 14-GENE SIGNATURE ASSOCIATED TO CHOLESTEROL METABOLISM IDENTIFIES M1-LIKE TUMOR-INFILTRATING MACROPHAGES AND PREDICTS PATIENT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA (2019) (0)
- Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients (2018) (0)
- Treatment of Severe Aplastic Anaemia (SAA) with Antilymphocyte Globulin (ALG), Cyclosporine (CyA) and Granulocyte Colony Stimulating Factor (G-CSF) 5 μG vs 10 μG/Kg : A Gitmo Prospective Randomized Study. (2004) (0)
- Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia (2000) (0)
- Stage B multiple myeloma patients: a long-term, single center outcomes research study (2014) (0)
- Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group (2016) (0)
- Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV) (2008) (0)
- Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL) (2007) (0)
- THIOTEPA-BASED CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOID LEUKEMIA (AML) - A SURVEY FROM THE ALWP OF THE EBMT (2014) (0)
- Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients. (2012) (0)
- polycythemia vera or essential thrombocythemia Clinical profile of homozygous JAK2 617V>F mutation in patients with (2013) (0)
- Editor's/Publisher's Disclaimer (1998) (0)
- Imatinib long term effects study: three years of follow-up and assessment (2009) (0)
- Human Anti Cancer Cytokine Induced Killer Cells and TheirInteraction With the Host Immune System (2011) (0)
- Post-liver transplantation recurrence of primary sclerosing cholangitis: role of autologous hematopoietic stem cell transplantation (2023) (0)
- monocytes Independent regulation of M-CSF and G-CSF gene expression in human (2011) (0)
- Second hematopoietic stem cell transplantation from unrelated donor in severe aplastic anemia. A retrospective analysis from the Aplastic Anemia Working party (SAA-WP). (2012) (0)
- Molecular genetics of the t(15;17) translocation in acute promyelocytic leukemia. (1993) (0)
- its expression by leukemic cells myeloblastic leukemia by interleukin-1 receptor antagonist and lack of Modulation of cell proliferation and cytokine production in acute (2011) (0)
- Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study (2014) (0)
- Peripheral blood progenitor cells for allogenic transplantation of resistant and relapsing acute leukemias Molecular evidence of full hematologic engraftment (1996) (0)
- P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19 (2022) (0)
- Effect ofastreptococcal preparation (OK432) onnatural killer activity oftumour-associated lymphoid cells inhuman ovarian carcinoma andonlysis offresh ovarian tumourcells (1983) (0)
- Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00. (2007) (0)
- Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) Retrospective Study on 1,266 Patients. (2006) (0)
- High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera. (2009) (0)
- phase 1/2 study in patients with myelofibrosis Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a (2012) (0)
- P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers (2022) (0)
- LOW-DOSE TBI-BASED NON-MYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MULTIPLE MYELOMA (2004) (0)
- Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year (2011) (0)
- AUTOGRAFTING FOLLOWED BY LOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING IN MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2003) (0)
- Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma (2021) (0)
- Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS) (2022) (0)
- leukemias with the t(4;11) translocation polymerase chain reaction for diagnosis and monitoring of acute Detection of ALL-1/AF4 fusion transcript by reverse transcription- (2011) (0)
- disorders Molecular histogenesis of posttransplantation lymphoproliferative (2011) (0)
- Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study. (2007) (0)
- The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making (2013) (0)
- Malignant LymphomasResearch Paper (2004) (0)
- Caspofungin primary antifungal prophylaxis in acute leukemia patients during induction therapy : results of a prospective phase ii multicentric study (profilc study) (2009) (0)
- Ultra Rapid, One Step Molecular Detection of BCR-ABL Major and Minor Transcripts by Isothermal RT-Loop Mediated Amplification Reaction. (2012) (0)
- Allogeneic Stem Cell Transplantation from Two Loci Mismatched (≤6/8) Unrelated Donors in Acute Leukemia: On Behalf of the ALWP of the EBMT (2020) (0)
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (0)
- Chronic Myeloid Leukemia: Molecular Monitoring of Residual Disease by Genomic DNA Compared to Conventional mRNA Analysis in Follow-Ups up to 8 Years (2011) (0)
- Assessing residual disease in imatinib-treated CML patients by DNA compared to MRNA assays (2008) (0)
- Frequent nonmalignant genetic alterations occurrence in clinical grade Mesenchymal Stromal Cells expanded for Cell Therapy Protocols (2014) (0)
- Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial (2017) (0)
- Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (2001) (0)
- PLK1 expression in AML-NS8 cells and activity of PLK1 inhibitor NMS-937 in vitro and in vivo . (2013) (0)
- Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms. (2009) (0)
- In Adult Acute Lymphoblastic Leukemia End of Induction MRD Correlates Strongly with Subsequent Key Timepoints and Predicts Long Term Outcome (2017) (0)
- Autologous Vs Related Vs Unrelated Hematopoietic Stem Cell Transplantation for Adults with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the EBMT (2017) (0)
- ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING A REDUCED INTENSITY CONDITIONING REGIMEN IN RELAPSED PERIPHERAL T-CELL LYMPHOMAS (PTCL): RESULTS AFTER A MEDIAN FOLLOW-UP OF 67 MONTHS (2011) (0)
- Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: The GITMO (gruppo italiano trapianto midollo osseo) experience (2007) (0)
- PO-52 Determination of thrombin generation (TG) and procoagulant activity (PCA) expressed by circulating microparticles (MP) in essential thrombocythemia (ET) patients (2010) (0)
- Author Correction: High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias (2023) (0)
- PB2192 GLOBAL COAGULATION CAPACITY OF ESSENTIAL THROMBOCYTHEMIA PATIENTS BY ROTEM ANALYSIS ADJUSTED FOR PLATELET COUNT CORRELATES WITH THROMBOTIC RISK CLASS (2019) (0)
- Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) (2012) (0)
- PO-25 Predictive value for VTE of hemostatic markers in patients with multiple myeloma receiving thalidomide (2007) (0)
- Sequential allogenic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive Myeloid Sarcoma and Acute B-Lymphoblastic Leukemia (2021) (0)
- Malignant Lymphomas Anti-CD 20 antibody ( rituximab ) administration in patients with late-occurring lymphomas after solid organ transplant (0)
- Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study (2016) (0)
- Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party (2018) (0)
- Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor. (2006) (0)
- Use of antibodies against surface antigens for the treatment of graft versus host disease (1999) (0)
- Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP) (2021) (0)
- Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients. (2009) (0)
- Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy (2015) (0)
- Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19 (2021) (0)
- Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) has better EFS and PFS than R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: A multicenter randomized GITMO/IIL trial. (2006) (0)
- WHO CLASSIFICATION AND WPSS PREDICT POST-TRANSPLANT OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS OF A RETROSPEC (2008) (0)
- T-cell receptor gene rearrangements and expression in normal human large granular lymphocytes (LGL) and their pathological expansions (1987) (0)
- High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt (2018) (0)
- Factors determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a survey from the Acute Leukaemia Working Party of the EBMT (2015) (0)
- Title : Targeting CDK 6 and BCL 2 exploits the “ MYB addiction ” of Ph + acute lymphoblastic leukemia (2017) (0)
- Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients (2010) (0)
- Randomized Trial Comparing R-chop-14 Versus High Dose Sequential Chemotherapy in High Risk Patients with Diffuse Large B-cell Lymphomas. Final results from the Gitil-rhds0305 study: O064 (2016) (0)
- New Isoforms of the ZFM1 Gene: a Growing Family of Signal Transduction and Activator of RNA (STAR) Proteins (1998) (0)
- essential thrombocythemia Characteristics and clinical correlates of MPL 515W>L/K mutation in (2013) (0)
- The importance of differential diagnosis between Bronj and hematologic diseases. (2013) (0)
- leukemia Constitutive expression of the interleukin-6 gene in chronic lymphocytic (2011) (0)
- REDUCED-INTENSITY CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS (2004) (0)
- Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population (2012) (0)
- INTEGRATING TUMOR‐ AND MICROENVIRONMENT‐REFLECTING GENES IN A UNIQUE AND ROUTINE‐APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL (2019) (0)
- Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older Than 60 Years. (2004) (0)
- Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO) (2022) (0)
- Efficacy of High-Dose Sequential Chemotherapy and Autograft for Transformed Non Hodgkin’s B Cell Lymphoma: Results of a Retrospective Analysis from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). (2007) (0)
- Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial (2017) (0)
- Abstract 2207: A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). (2013) (0)
- PF655 PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS (2019) (0)
- Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response (2022) (0)
- Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial (2017) (0)
- P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials (2022) (0)
- JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia. (2005) (0)
- Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN) (2022) (0)
- TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2007) (0)
- Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT (2022) (0)
- Establishment and Characterization of a New Granulocyte-Macrophage Colony-Stimulating Factor-Dependent and Interleukin-3-Dependent Human Acute Myeloid Leukemia Cell Line ( GF-DS ) (2003) (0)
- Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL). (2007) (0)
- A phase II study on intensive all type chemotherapy with minimal residual disease (MRD) oriented postremission strategy in adult patients with lymphoblastic lymphoma(PROTOCOL NILG-ALL NO.09/00) (2008) (0)
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (0)
- Permissive HLA-DPB1 Mismatch and Survival after Unrelated Donor Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Comparative Analysis of Different Immunogenetic Models on 422 Patients from GITMO and IBMDR (2018) (0)
- Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation (2022) (0)
- PF436 GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY (2019) (0)
- Combination with Chemotherapy Leukemia Cells in Whole Blood and in Rituximab in Lysing B Chronic Lymphocytic Ofatumumab Is More Efficient than (2012) (0)
- Rare High Risk IgH Translocations in Newly Diagnosed Multiple Myeloma (MM): Cytogenetic Characterization and Relevance on Prognosis (2015) (0)
- Unrelated cord blood (ECB) transplantation for AML: higher incidence of acute GVHD and lower survival in male patients transplanted with female unrelated cord blood. A report from Eurocord and the ALWP of the EBMT (2015) (0)
- Newly-Diagnosed, Non-Transplant Eligible Multiple Myeloma Patients: Determinants of Choice of First-Line Treatment in a Single-Center (2019) (0)
- AUTOGRAFTING FOLLOWED BY NON MYELOABLATIVE TBI-BASED ALLOGRATING FOR TREATMENT OF MULTIPLE MYELOMA: A MULTI-CENTER TRIAL (2002) (0)
- Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT (2014) (0)
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT, (2011) (0)
- Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS) (2016) (0)
- S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA (2019) (0)
- ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION (2017) (0)
- Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. (2019) (0)
- Platelet-Lysate-Expanded Mesenchymal Stromal Cells for the Treatment of Resistant GVHD (2011) (0)
- Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients – A Report From The Acute Leukemia Working Party Of EBMT (2013) (0)
- The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study) (2008) (0)
- Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab (2022) (0)
- INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT (2019) (0)
- Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients (2010) (0)
- Autologous stem cell transplantation (ASCT) in patients with POEMS syndrome results in durable symptomatic disease control: A retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancies Working Party of the EBMT (2015) (0)
- Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATCL): A Retrospective Study of the European Group for Blood and Marrow Transplantation (EBMT) (2011) (0)
- Use of histone deacetylase inhibitors for the treatment of negative myeloproliferative syndromes Philadelphia (2009) (0)
- Role of Front-Line High Dose Therapy with Stem Cell Transplant in Peripheral T-Cell Lymphomas. A Single Center Experience. (2012) (0)
- A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL) (2021) (0)
- polymorphonuclear leukocytes myelogenous leukemia and paroxysmal nocturnal hemoglobinuria Differences in the expression of alkaline phosphatase mRNA in chronic (2013) (0)
- NEXT GENERATION SEQUENCING (NGS) CONFIRMED THE ADVERSE CLINICAL IMPACT OF RUNX1 MUTATIONS IN A SUBSET OF ACUTE MYELOID LEUKEMIA NORMAL KARYOTYPE PATIENTS NEGATIVE FOR RISK DEFINING GENES MUTATIONS AND HOMOGENOUSLY TREATED WITHIN A CLINICAL TRIAL (NILG AML 02/06) (2017) (0)
- Subject Index Vol. 95, 1996 (1996) (0)
- Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis (2013) (0)
- Real time PCR for molecular monitoring of minimal residual disease in multiple myeloma patients undergoing autologous transplantation with in vitro purged hematopoietic stem cells (2000) (0)
- previously untreated patients with follicular lymphoma Monitoring of minimal residual disease after CHOP and rituximab in (2013) (0)
- Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy (2012) (0)
- dependent mechanism stimulate monocyte cytotoxicity through a tumor necrosis factor- Human granulocyte-monocyte colony-stimulating factor and interleukin 3 (2011) (0)
- Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm (2011) (0)
- High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias (2022) (0)
- Driver mutations ( JAK2 V617F , MPL W515L/K or CALR ), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera (2017) (0)
- JACIE accreditation status and outcome after hematopoietic stem cell transplantation (2014) (0)
- Breakthrough infections in MPN-COVID vaccinated patients (2022) (0)
- Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. (2022) (0)
- Allografting from unrelated donors in multiple myeloma: a study by the Italian bone marrow donor registry (2012) (0)
- Prospective Evaluation of Thrombo-Hemorrhagic Events and Hypercoagulation Markers in Patients with Acute Promyelocytic Leukemia (APL) Receiving All-Trans Retinoic Acid (ATRA) Plus Chemotherapy (2017) (0)
- Multidimensional Results and Reflections on CAR-T: The Italian Evidence (2023) (0)
- HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY (2006) (0)
- PS1257 LYMPHOCYTE TO MONOCYTE RATIO (LMR) PREDICTS PROGRESSION-FREE SURVIVAL INDEPENDENTLY FROM FLIPI AND IS USEFUL IN IDENTIFYING PATIENTS WITH EARLY DISEASE PROGRESSION (2019) (0)
- Flow Cytometry of Leukocyte Alkaline Phosphatase in Human Hematopoietic Cells (1998) (0)
- Short chemotherapy-phased imatinib (IM) pulses improve long-term outcome of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) (2009) (0)
- Development of an MF patient reported outcome (PRO) tool for FDA qualification: Comprehensive literature search and physician cognitive debriefing results (2016) (0)
- Transferability Of Results From Randomized Trials To Clinical Practice: The Case Of Diffuse Large B Cell Lymphoma Patients Treated With R-CHOP When Comorbidities Are Present (2013) (0)
- ONE-HUNDRED-EIGHT CONSECUTIVE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THE TANDEM AUTO-TBI BASED MINI-ALLO APPROCH (2006) (0)
- Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (2022) (0)
- PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE (2019) (0)
- 2 amongst patients undergoing autologous transplant for multiple myeloma : a multicentre UK study (2017) (0)
- Gene expression pro fi le correlates with molecular and clinical features in patients with myelo fi brosis (2021) (0)
- Reduced intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed non-Hodgkin’s and Hodgkin’s lymphomas (2006) (0)
- Unrelated bone marrow transplantation with reduced-intensity regimen in high-risk patients for age or disease: a prospective GITMO study (2005) (0)
- Upfront Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Aplastic Anemia: A Study on Behalf of the Saawp of EBMT (2020) (0)
- Gene Rearrangements and Expression in Normal and Leukemic Large Granular Lymphocytes / Natural Killer Cells (2005) (0)
- Nilotinib For Steroid-Refractory Chronic Graft Versus Host Disease (SR-cGVHD): Preliminary Results Of a Phase I-II GITMO Study (Gruppo Italiano Trapianto di Midollo Osseo) (2013) (0)
- Patterns of fatigue in patients with primary immune thrombocytopenia: a multicenter observational study (2013) (0)
- Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia (2014) (0)
- Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS: THE VEXAS/MDS ITALIAN EXPERIENCE (2023) (0)
- Expression of the T Cell Receptor δ Gene in Normal and Leukemic Natural Killer Cells1 (1990) (0)
- P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS (2022) (0)
- Next Generation Sequencing (NGS) of TP53 Gene Allows to Identify a Very High Risk Group of Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Patients (2014) (0)
- Clinical Relevance of JAK2 V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis (2008) (0)
- POST LIVER TRANSPLANT LINFOPROLIFERATIVE DISEASE: A PEDIATRIC CENTRE EXPERIENCE (2004) (0)
- Retrospective comparison of transplant from matched unrelated donor or identical sibling in adult MDS : evidence for a graft-versus-myelodysplasia effect in unrelated donor transplant (2007) (0)
- PO-28 Increased thrombin generation (TG) potential of platelets from myeloproliferative neoplasms (2010) (0)
- The Role of Anthracycline S in the Management of Adult Acute Lymphoblastic Leukaemia (1996) (0)
- Physicians Abstracts (2015) (0)
- Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT (2022) (0)
- Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL) : Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). (2012) (0)
- EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY (2009) (0)
- Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications (2018) (0)
- An International Multicenter Project on Secondary Myelofibrosis (2016) (0)
- Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkin’s Lymphoma. (2006) (0)
- The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation (2013) (0)
- Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls? (2012) (0)
- Genomic and Transcriptional Immunoediting of Acute Myeloid Leukemia in Response to Allogeneic Hematopoietic Stem Cell Transplantation (2011) (0)
- Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease (2016) (0)
- Interim-PET scan interpretation in the ongoing prospective clinical trial HD 0607, in advanced-stage Hodgkin lymphoma: Results of the the expert panel review (2010) (0)
- Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network (2017) (0)
- 25. Expression of the erythroid-specific transcription factor GATA-1 in human myeloid leunkenic cells (1992) (0)
- Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study (2022) (0)
- ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS (CN-AML): OUTCOME, RISK FACTORS AND ROLE OF MOLECULAR SUBGROUPS IN 1006 PATIENTS - A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT (2014) (0)
- Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol (2018) (0)
- Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) (2014) (0)
- Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group (2014) (0)
- Induction of cytotoxicity by interleukin-2 in T gamma-lymphoproliferative disorders. (1986) (0)
- Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia (2014) (0)
- Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis (2017) (0)
- Use of anti-CD20 antibodies for the treatment of graft-versus-host disease (2000) (0)
- Effects of Antiplatelet Treatment with Aspirin (ASA) on Platelet Reactivity in Patients with Essential Thrombocythemia (2016) (0)
- Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features (2016) (0)
- based on the burden of JAK2V617F mutated allele Identification of patients with poorer survival in primary myelofibrosis (2013) (0)
- Pharmacokinetic study of the new cyclosporine-a formulation (neoral™) in adult ALLO-BMT recipients (2000) (0)
- High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls. (2008) (0)
- Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL (2023) (0)
- Use of PCR for BCL2/IgH + cells in stage I/II follicular lymphoma to identify positive cells in bone marrow and peripheral blood that can be cleared by lymph-node irradiation (2008) (0)
- (IPSET-thrombosis) essential thrombocythemia - thrombosis in World Health Organization Development and validation of an International Prognostic Score of (2013) (0)
- S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD (2019) (0)
- Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden. (2008) (0)
- REDUCED INTENSITY ALLOGENEIC SCT ACHIEVES LONG TERM DISEASE CONTROL IN PATIENTS WITH FOLLICULAR LYMPHOMA RELAPSING AFTER A PRIOR AUTOLOGOUS SCT AND MAY OVERCOME THE ADVERSE IMPACT OF EARLY RELAPSE POST AUTOSCT. AN EBMT LYMPHOMA WORKING PARTY ANALYSIS (2014) (0)
- Autoimmunity and second malignancy in large granular lymphocytic leukaemia. (1989) (0)
- Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy (2012) (0)
- Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes (2022) (0)
- Stem cell transplantation for BCR-ABL1-positive and negative myeloproliferative neoplasms (2020) (0)
- Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia--Authors' reply. (2016) (0)
- PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (0)
- Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation (2019) (0)
- TANDEM AUTO-MINI ALLO APPROACH FOR NEWLY DIAGONSED MULTIPLE MYELOMA: AN UPDATE OF THE ITALIAN EXPERIENCE (2005) (0)
- Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT (2012) (0)
- essential thrombocythemia, polycythemia vera, and myelofibrosis Long-term survival and blast transformation in molecularly annotated (2014) (0)
- Time- and Dose-Response Relationships of Imatinib Mesylate (Glivec) Therapy for Chronic Hypereosinophilic Syndromes. (2005) (0)
- PF435 A FLEXIBLE THERAPEUTIC STRATEGY FOR LEUKEMIA USING EX-VIVO EXPANDED T CELLS COMBINED WITH BISPECIFIC ANTIBODIES (2019) (0)
- Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis (2022) (0)
- Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score (2022) (0)
- Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies (2017) (0)
- High-Dose Sequential Chemotherapy (HDS) Followed by Autologous Stem Cell Transplantation (ASCT) in Relapsing/Refractory Hodgkin Lymphoma (HL): Long-Term Results. (2007) (0)
- Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. (2022) (0)
- Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia (2022) (0)
- The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program. (2007) (0)
- Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Represents a Feasible and Effective Treatment Strategy for Advanced Mycosis Fungoides and Sezary Syndrome. (2006) (0)
- Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis (2022) (0)
- Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey (2022) (0)
- Contents, Vol. 95, 1996 (1996) (0)
- High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp (2010) (0)
- Cytokine Induced Killer Cells Can Kill Target through Antigen/TCR Dependent and Independent Mechanisms: New Clinical Perspectives of Utilisation. (2009) (0)
- Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission (2012) (0)
- Outcome of Two Loci Mismatched (≤6/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study (2019) (0)
- and Allogeneic Transplantation Mobilized Circulating Progenitor Cells: Adequacy for Autologous - Factor Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating (2013) (0)
- Identification By Gene Expression Profiling Of CIITA-Dependent HLA Class II Transcriptional Downregulation As a Novel Mechanism Of Leukemia Immune Escape and Relapse After Allogeneic HSCT (2013) (0)
- Erratum: Platelet‐induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera (2011) (0)
- Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis (2017) (0)
- DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface (2022) (0)
- Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients (2012) (0)
- Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia (2010) (0)
- Interleukin-1 3 and Tumor Necrosis Factor-ot Induce Gene Expression and Production of Leukocyte Chemotactic Factors, Colony-stimulating Factors, and Interleukin-6 in Human Mesangial Cells (2007) (0)
- A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL). (2004) (0)
- Identification of chromosomal rearrangements in the human myeloid leukemia cell line GF‐D8 by dual‐colour fluorescence in situ hybridization (1995) (0)
- Skip pattern approach toward the early access of innovative anticancer drugs (2021) (0)
- Abstract CT025: NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience (2023) (0)
- How important is to eradicate minimal residual disease in indolent non-Hodgkin’s lymphoma? (2009) (0)
- MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG) (2018) (0)
- Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord (2018) (0)
- Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study (2022) (0)
- Abstract 1324: NMS-P088, a novel FLT3, KIT and CSF1R inhibitor, is a promising clinical candidate for AML and CMML treatment (2019) (0)
- second intron. Italian Cooperative Study Group "GIMEMA" leukemia (APL) and mapping of APL breakpoints within the RAR-alpha alpha (RAR-alpha) locus in all patients with acute promyelocytic Identification of DNA rearrangements at the retinoic acid receptor- (2013) (0)
- Poster Sessions I and II , Interdisciplinary Workshop, Satelite Symposia I-IV (2004) (0)
- JAK2V617F Mutation and Thrombosis History Are Determinants of Mean Platelet Volume (MPV) in Essential Thrombocythemia Patients (2016) (0)
- High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study. (2009) (0)
- Phase II Study of Sequential Infusion of DLI and Cytokine Induced Killer Cells for Patients Relapsed after Sequential for (2017) (0)
- Epitope Engineered Hematopoietic Stem and Progenitor Cells to Enable CAR-T Cell Immunotherapy for Acute Myeloid Leukemia (2022) (0)
- Pegylated Interferon Alpha – 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases (2011) (0)
- MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY) (2015) (0)
- Relevance of amino acid 116 substitutions on the outcome of hla class I mismatched bone marrow transplants (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alessandro Rambaldi?
Alessandro Rambaldi is affiliated with the following schools:
